Atorvia, Ottawa-based company developing novel treatments that target the molecular causes underlying kidney damage, was named the inaugural winner of the Blue Ticket competition at the University of Toronto Mississauga’s SpinUp wet lab incubator. Sponsored by pharmaceutical company Merck, the Blue Ticket program aims to empower the next generation of global health innovators. Atorvia will receive a free one-year membership to SpinUp, an up-front cash prize and mentorship from scientific, and business leaders at Merck.
Atorvia is an alumnus of our HealthMINT™ and WiHI Seed programs, and presented at the OBIO® Investment Summit.